{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:38:40Z","timestamp":1774251520644,"version":"3.50.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Recombinant human thrombopoietin (rhTPO) has been shown to improve platelet (PLT) counts in chronic liver disease (CLD)-associated thrombocytopenia (TP). However, whether concomitant infections influence its efficacy remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective study of 259 patients with CLD-associated TP who received rhTPO at Henan Provincial People\u2019s Hospital from January 2021 to October 2023. Patients were divided into concomitant infection (n = 178) and non-concomitant infection (n = 81) groups. Primary endpoints were the response rate and time to response. Secondary endpoints included the platelet transfusion requirements, PLT recovery differences and factors influencing rhTPO efficacy. Propensity score matching (PSM) was applied to adjust for baseline confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 1:1 PSM (n = 132), the overall response rate was 57.6% and the median time to response was 10 days, with no serious adverse events observed. Response rates and response time were comparable between concomitant infection and non-concomitant infection groups (59.1% vs. 56.1%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.725; 10 days vs. 11 days,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.442). rhTPO significantly increased PLT counts from Day 3 in patients without concomitant infection and from Day 5 in those with concomitant infection. Both groups maintained elevated levels at 14 days post-discontinuation and remained above baseline until 28 days after discontinuation. No significant differences between the two groups were observed at any time point. Patients with concomitant infection had a significant higher platelet transfusion rate than those without infections (22.7% vs. 7.6%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.015). Sensitivity analysis excluding these transfused patients showed consistent efficacy of rhTPO regardless of infection status. Multivariable analyses identified Child\u2013Pugh C and cirrhosis as independent factors associated with response and time to response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>rhTPO was associated with improved PLT counts in CLD-associated TP without serious adverse events. This efficacy appeared comparable regardless of concomitant infection status. Liver function reserve may be the major determinant of efficacy. Prospective multicenter studies are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1732969","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:44:19Z","timestamp":1774248259000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Recombinant human thrombopoietin for chronic liver disease-associated thrombocytopenia with or without concomitant infections: a real-world retrospective study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xun","family":"Wei","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen Bo","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya Mei","family":"Kuang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin Meng","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun Feng","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/tri.12064","article-title":"Peripheral platelet count correlates with liver atrophy and predicts long-term mortality on the liver transplant waiting list","volume":"26","author":"Bleibel","year":"2013","journal-title":"Transpl. Int."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3410\/M2-5","article-title":"Platelet transfusions: trigger, dose, benefits, and risks","volume":"2","author":"Blumberg","year":"2010","journal-title":"F1000 Medicine Reports"},{"key":"B3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3760\/cma.j.issn.0253-3766.2018.09.014","article-title":"Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)","volume":"40","year":"2018","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103459","DOI":"10.1016\/j.eclinm.2025.103459","article-title":"Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (the TE-ITP study)","volume":"87","author":"Chen","year":"2025","journal-title":"EClinicalMedicine"},{"key":"B5","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"J. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1378\/chest.124.3.1016","article-title":"Cirrhosis as a risk factor for sepsis and death: analysis of the national Hospital Discharge Survey","volume":"124","author":"Foreman","year":"2003","journal-title":"Chest"},{"key":"B7","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1155\/2014\/532191","article-title":"Management of Thrombocytopenia in advanced liver disease","volume":"28","author":"Gangireddy","year":"2014","journal-title":"Can. J. Gastroenterology Hepatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/gut.44.5.754","article-title":"Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation","volume":"44","author":"Goulis","year":"1999","journal-title":"Gut"},{"key":"B9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1002\/hep.26372","article-title":"An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome","volume":"58","author":"Hugenholtz","year":"2013","journal-title":"Hepatology"},{"key":"B10","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1440-1746.1998.tb00760.x","article-title":"Reduced expression of thrombopoietin is involved in thrombocytopenia in human and rat liver cirrhosis","volume":"13","author":"Ishikawa","year":"1998","journal-title":"J Gastro Hepatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12185-013-1382-0","article-title":"The biology of thrombopoietin and thrombopoietin receptor agonists","volume":"98","author":"Kuter","year":"2013","journal-title":"Int. J. Hematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17474124.2021.1842732","article-title":"Angiogenesis in the progression from liver fibrosis to cirrhosis and hepatocelluar carcinoma","volume":"15","author":"Li","year":"2021","journal-title":"Expert Review Gastroenterology and Hepatology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s12185-018-2445-z","article-title":"Chinese guidelines for treatment of adult primary immune thrombocytopenia","volume":"107","author":"Liu","year":"2018","journal-title":"Int. J. Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"105004","DOI":"10.3748\/wjg.v31.i14.105004","article-title":"Efficacy of recombinant human thrombopoietin in patients with acute-on-chronic liver failure and thrombocytopenia: a prospective, open-label study","volume":"31","author":"Liu","year":"2025","journal-title":"World J. Gastroenterol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/s40265-015-0480-0","article-title":"Management of Thrombocytopenia in chronic liver disease: focus on pharmacotherapeutic strategies","volume":"75","author":"Maan","year":"2015","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","article-title":"Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions","volume":"21","author":"Mak","year":"2024","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B17","first-page":"326","article-title":"Thrombocytopenia in chronic liver disease and the role of thrombopoietin agonists","volume":"15","author":"Miller","year":"2019","journal-title":"Gastroenterol. Hepatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/HMER.S74612","article-title":"The pathophysiology of thrombocytopenia in chronic liver disease","volume":"8","author":"Mitchell","year":"2016","journal-title":"Hepatic Medicine Evidence Research"},{"key":"B19","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/liv.13317","article-title":"Thrombocytopenia in chronic liver disease","volume":"37","author":"Peck-Radosavljevic","year":"2017","journal-title":"Liver Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"5421632","DOI":"10.1155\/2020\/5421632","article-title":"Avatrombopag, an alternate treatment option to reduce platelet transfusions in patients with thrombocytopenia and chronic liver disease\u2010integrated analyses of 2 phase 3 studies","volume":"1","author":"Poordad","year":"2020","journal-title":"Int. J. Hepatology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"896","DOI":"10.3760\/cma.j.cn501113-20200609-00304","article-title":"Management strategies for chronic liver disease-related thrombocytopenia","volume":"29","author":"Qian","year":"2021","journal-title":"Chin. Journal Hepatology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1182\/hematology.2021000283","article-title":"Rebalanced hemostasis in liver disease: a misunderstood coagulopathy","volume":"2021","author":"Roberts","year":"2021","journal-title":"Hematology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1128\/mcb.17.9.4991","article-title":"Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase Pathway","volume":"17","author":"Rouyez","year":"1997","journal-title":"Mol. Cell. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1007\/s10620-019-05615-5","article-title":"Management of Thrombocytopenia in patients with chronic liver disease","volume":"64","author":"Saab","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"B25","first-page":"1040","article-title":"The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases","volume":"23","author":"Sattler","year":"1995","journal-title":"Exp. Hematology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1182\/blood-2009-06-227033","article-title":"Ubiquitination and degradation of the thrombopoietin receptor c-Mpl","volume":"115","author":"Saur","year":"2010","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.3390\/jcm10071530","article-title":"Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management","volume":"10","author":"Scharf","year":"2021","journal-title":"J. Clin. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"Jama"},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/JBM.S234374","article-title":"Platelet transfusion: and update on challenges and outcomes","volume":"11","author":"Solves Alcaina","year":"2020","journal-title":"JBM"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.3390\/biomedicines12102229","article-title":"Liver fibrosis leading to cirrhosis: basic mechanisms and clinical perspectives","author":"Somnay","year":"2024","journal-title":"Biomedicines"},{"key":"B31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/bjh.13597","article-title":"Platelet refractoriness\u2013practical approaches and ongoing dilemmas in patient management","volume":"171","author":"Stanworth","year":"2015","journal-title":"Br. Journal Haematology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000355006","article-title":"Clinical indications for thrombopoietin and thrombopoietin-receptor agonists","volume":"40","author":"W\u00f6rmann","year":"2013","journal-title":"Transfus. Med. Hemotherapy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.jcrc.2013.11.023","article-title":"Recombinant human thrombopoietin improves platelet counts and reduces platelet transfusion possibility among patients with severe sepsis and thrombocytopenia: a prospective study","volume":"29","author":"Wu","year":"2014","journal-title":"J. Crit. Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jointm.2023.12.006","article-title":"Recombinant human thrombopoietin in alleviating endothelial cell injury in sepsis","volume":"4","author":"Xie","year":"2024","journal-title":"J. Intensive Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4718","DOI":"10.7150\/jca.26690","article-title":"A randomized controlled study of rhTPO and rhIL-11 for the prophylactic treatment of chemotherapy-induced thrombocytopenia in non-small cell lung cancer","volume":"9","author":"Xu","year":"2018","journal-title":"J. Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4990","DOI":"10.1182\/blood-2018-99-116000","article-title":"Recombinant human Thrombopoietin increases platelet numbers and reduces the risk of bleeding events in thrombocytopenic patients with chronic hepatitis B virus infection: a multicenter observational Study","volume":"132","author":"Zhai","year":"2018","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"155227","DOI":"10.1016\/j.cyto.2020.155227","article-title":"Prognosis and rescue therapy for sepsis-related severe thrombocytopenia in critically ill patients","volume":"136","author":"Zhou","year":"2020","journal-title":"Cytokine"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1732969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:44:21Z","timestamp":1774248261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1732969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1732969"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1732969","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"1732969"}}